ClinicalTrials.gg
CompletedNCT04686136Updated Dec 18, 2025

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

A Phase 3 interventional study of Atogepant 60 mg in Episodic Migraine and Chronic Migraine, sponsored by AbbVie. Completed at 116 sites in 14 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
596
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Enrollment
9th of 21
596 · median 468
Started
2021
with 3 others
Phase 3
15 of 21
3 open now
Registered
7th of 21
by date
Lead sponsor
11 of 21
AbbVie

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 9th largest by enrollment, is one of 4 that started in 2021, is one of 15 in phase 3, and was the 7th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine

03

Conditions studied

  • Episodic Migraine
  • Chronic Migraine

Browse trials for

Keywords

  • Episodic migraine
  • Chronic migraine
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Eligible participants who completed Visit 7, and Visit 8 if applicable, of Study 3101-303-002 or Study 3101-304-002 without significant protocol deviations and who did not experience an Adverse Event that may indicate an unacceptable safety risk.

Exclusion criteria

Exclusion Criteria:

  • Participants requiring any medication, diet, or nonpharmacological treatment on the list of prohibited concomitant medications or treatments that cannot be discontinued or switched to an allowable alternative.
  • Participants with an indicating abnormalities at Visit 1.
  • Participants with hypertension at Visit 1.
  • Participants with a significant risk of self-harm, or of harm to others; participants who report suicidal ideation with intent, with or without a plan, since the last visit, must be excluded.
  • Participants with clinically significant hematologic, endocrine, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
596 participants (actual)

Study arms

  • Experimental
    Atogepant 60 mg

    Taken once daily

    Drug: Atogepant 60 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with at Least 1 Treatment Emergent Adverse Event

    Time frame: 156 weeks

Secondary outcomes

  1. Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, Hematology, Urinalysis) as assessed by the Investigator

    Time frame: 156 weeks

  2. Percentage of Participants with Clinically Significant Electrocardiograms (ECGs) Findings as assessed by the Investigator

    Time frame: 156 weeks

  3. Percentage of Participants with Clinically Significant Vital Sign Measurements as assessed by the Investigator

    Time frame: 156 weeks

  4. Columbia-Suicide Severity Rating Scale (C-SSRS) Assessing Suicidal Ideation and Behaviour using 5-Point Scales

    A clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior)

    Time frame: 156 weeks

07

Study locations

116 sites
  • Duplicate_Barrow Neurological Institute /ID# 228217
    Phoenix, Arizona 85013-4407, United States
  • California Headache and Balance Center /ID# 226241
    Fresno, California 93720, United States
  • Duplicate_Pharmacology Research Institute (PRI) - Los Alamitos (Wake) /ID# 226404
    Los Alamitos, California 90720-3500, United States
  • Pharmacology Research Institute (PRI) - Newport Beach (Wake) /ID# 226389
    Newport Beach, California 92660, United States
  • Excell Research, Inc /ID# 228390
    Oceanside, California 92056, United States
  • Duplicate_Schuster Medical Research Institute /ID# 226246
    Sherman Oaks, California 91403, United States
  • Alpine Clinical Research Center /ID# 226203
    Boulder, Colorado 80301-1880, United States
  • Sensible Healthcare /ID# 226426
    Ocoee, Florida 34761, United States
  • Accel Research Sites - Tampa Clinical Research Unit /ID# 226252
    Tampa, Florida 33634, United States
  • NeuroTrials Research Inc /ID# 226477
    Atlanta, Georgia 30342, United States
  • Allied Physicians - Fort Wayne Neurological Center /ID# 226390
    Fort Wayne, Indiana 46804, United States
  • Josephson-Wallack-Munshower Neurology - Northeast /ID# 226295
    Indianapolis, Indiana 46256, United States
  • Collective Medical Research /ID# 226482
    Overland Park, Kansas 66210, United States
  • Ochsner Clinic Foundation /ID# 228220
    Covington, Louisiana 70433-8107, United States
  • Pharmasite Research, Inc. /ID# 226444
    Baltimore, Maryland 21208, United States
  • Beth Israel Deaconess Medical Center /ID# 228214
    Boston, Massachusetts 02215-5400, United States
  • BTC of New Bedford /ID# 226289
    New Bedford, Massachusetts 02740, United States
  • Clinical Research Institute, Inc /ID# 226232
    Minneapolis, Minnesota 55402-2606, United States
  • Headache Neurology Research Institute /ID# 226234
    Ridgeland, Mississippi 39157, United States
  • StudyMetrix Research /ID# 226296
    City of Saint Peters, Missouri 63303, United States
  • Clinvest Research LLC /ID# 226275
    Springfield, Missouri 65807, United States
  • Methodist Physicians Clinic/CCT Research /ID# 226422
    Fremont, Nebraska 68025, United States
  • Albuquerque Clinical Trials, Inc. /ID# 226523
    Albuquerque, New Mexico 87102, United States
  • Albany Medical Center Rheumatology /ID# 228212
    Albany, New York 12208-3412, United States
  • Headache Wellness Center /ID# 226233
    Greensboro, North Carolina 27405, United States
  • Duplicate_CTI Clinical Research Center /ID# 226278
    Cincinnati, Ohio 45212, United States
  • Stetson-University of Cincinnati /ID# 226326
    Cincinnati, Ohio 45219, United States
  • Abington Neurological Associates - Abington /ID# 226449
    Abington, Pennsylvania 19001, United States
  • Preferred Primary Care Physicians, Inc. /ID# 226447
    Pittsburgh, Pennsylvania 15236, United States
  • Mount Vernon Clinical Research /ID# 226249
    Chattanooga, Tennessee 37421, United States
  • CNS Healthcare - Memphis /ID# 226254
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials of Neurology /ID# 226424
    Austin, Texas 78731, United States
  • Austin Clinical Trial Partners /ID# 228391
    Austin, Texas 78737, United States
  • DiscoveResearch, Inc /ID# 226490
    Bryan, Texas 77802, United States
  • Texas Neurology /ID# 226425
    Dallas, Texas 75214, United States
  • LinQ Research, LLC /ID# 226391
    Pearland, Texas 77584, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic /ID# 226248
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. Foothill Family Clinic South /ID# 226328
    Salt Lake City, Utah 84121, United States
  • Highland Clinical Research /ID# 226287
    Salt Lake City, Utah 84124, United States
  • Sentara Family Medicine Physicians /ID# 226448
    Virginia Beach, Virginia 23456, United States
  • Northwest Clinical Research Center /ID# 226240
    Bellevue, Washington 98007, United States
  • Puget Sound Neurology /ID# 226253
    Tacoma, Washington 25328, United States
  • CHAMP Clinic /ID# 226256
    Calgary, Alberta T3M 1M4, Canada
  • Vancouver Island Health Authority /ID# 226255
    Victoria, British Columbia V8R 1J8, Canada
  • Aggarwal and Associates Limited /ID# 226452
    Brampton, Ontario L6T 0G1, Canada
  • Ottawa Headache Centre Research Inc /ID# 226451
    Ottawa, Ontario K2G 6E2, Canada
  • Diex Recherche Sherbrooke Inc. /ID# 226427
    Sherbrooke, Quebec J1L 0H8, Canada
  • CCR Ostrava, s.r.o. /ID# 228412
    Ostrava, Ostrava-mesto 702 00, Czechia
  • A-Shine s.r.o. /ID# 226207
    Pilsen, Plzeň Region 301 00, Czechia
  • NeuroHK s.r.o. /ID# 226429
    Hradec Králové, 500 09, Czechia
  • BRAIN-SOULTHERAPY s.r.o. /ID# 226394
    Kladno, 272 01, Czechia
  • Pratia Pardubice a.s. /ID# 226393
    Pardubice, 530 02, Czechia
  • Clintrial s.r.o. /ID# 228413
    Prague, 100 00, Czechia
  • DADO MEDICAL s.r.o. /ID# 226421
    Prague, 120 00, Czechia
  • Pratia Prague s.r.o. /ID# 226406
    Prague, 130 00, Czechia
  • Fakultni Thomayerova nemocnice /ID# 228409
    Prague, 140 59, Czechia
  • FORBELI s.r.o. /ID# 228406
    Prague, 160 00, Czechia
  • INEP medical s.r.o. /ID# 228411
    Prague, 186 00, Czechia
  • Vestra Clinics s.r.o. /ID# 226453
    Rychnov nad Kněžnou, 516 01, Czechia
  • NeuroMed Zlin s.r.o. /ID# 228414
    Zlín, 760 01, Czechia
  • Rigshospitalet Glostrup /ID# 228417
    Glostrup Municipality, Capital Region 2600, Denmark
  • CHU Nice - Hopital de Cimiez /ID# 228419
    Nice, Alpes-Maritimes 06000, France
  • AP-HM - Hopital de la Timone /ID# 226407
    Marseille, Bouches-du-Rhone 13385, France
  • Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord /ID# 228418
    St-Priest-en-Jarez, Pays de la Loire Region 42270, France
  • Duplicate_Hôpital Pierre Wertheimer /ID# 226430
    Bron, Rhone 69677, France
  • CHU Clermont Ferrand - Hopital Gabriel Montpied /ID# 226459
    Clermont-Ferrand, 63000, France
  • AP-HP - Groupe Hospitalier 10e - Hopital Lariboisiere /ID# 226220
    Paris, 75010, France
  • Neuropoint GmbH /ID# 226313
    Ulm, Baden-Wurttemberg 89073, Germany
  • Neuropraxis Muenchen Sued /ID# 226309
    Unterhaching, Bavaria 82008, Germany
  • Klinische Forschung Hannover-Mitte GmbH /ID# 226305
    Hanover, Lower Saxony 30159, Germany
  • Studienzentrum Nord-West /ID# 226310
    Westerstede, Lower Saxony 26655, Germany
  • AmBeNet GmbH /ID# 226312
    Leipzig, Saxony 04107, Germany
  • Schmerzklinik Kiel /ID# 226454
    Kiel, Schleswig-Holstein 24149, Germany
  • Zentrum für Neurologie, Neurochirurgie und Psychiatrie /ID# 229991
    Berlin, 10117, Germany
  • Praxis Dr. Gendolla /ID# 229988
    Essen, 45133, Germany
  • Universitaetsklinikum Essen /ID# 229989
    Essen, 45147, Germany
  • Vitos Orthopaedische Klinik Kassel gemeinnuetzige GmbH /ID# 231571
    Kassel, 34131, Germany
  • Velocity Clinical Research /ID# 226307
    Wiesbaden, 65189, Germany
  • Gyongyosi Bugat Pal Korhaz /ID# 228429
    Gyöngyös, Heves County 3200, Hungary
  • Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 226409
    Kaposvár, Somogy County 7400, Hungary
  • Clinexpert Kft /ID# 228431
    Budapest, 1033, Hungary
  • S-Medicon Kft /ID# 228432
    Budapest, 1138, Hungary
  • Azienda Ospedaliero Universitaria Careggi /ID# 228624
    Florence, Firenze 50134, Italy
  • Ospedale Ss. Filippo e Nicola /ID# 228627
    Avezzano, L Aquila 67051, Italy
  • Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 228625
    Milan, Milano 20133, Italy
  • IRCCS San Raffaele /ID# 228436
    Rome, Roma 00163, Italy
  • Universita di Pavia /ID# 228628
    Pavia, 27100, Italy
  • Fondazione Policlinico Universitario Campus Bio-Medico /ID# 228630
    Roma, 00128, Italy
  • Canisius-Wilhelmina Ziekenhuis /ID# 226410
    Nijmegen, Gelderland 6532 SZ, Netherlands
  • ZorgSaam Zorggroep Zeeuws-Vlaanderen /ID# 226456
    Terneuzen, Zeeland 4535 PA, Netherlands
  • Solumed Centrum Medyczne /ID# 226298
    Poznan, Greater Poland Voivodeship 60-529, Poland
  • Vitamed Galaj i Cichomski Sp.j. /ID# 226416
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-079, Poland
  • Specjalistyczne Gabinety Sp. z o.o. /ID# 228631
    Krakow, Lesser Poland Voivodeship 30-539, Poland
  • Centrum Leczenia Padaczki i Migreny /ID# 226458
    Krakow, Lesser Poland Voivodeship 31-209, Poland
  • Indywidualna Praktyka Lekarska dr hab. med. Anna Szczepanska-Szerej /ID# 226412
    Lublin, Lublin Voivodeship 20-582, Poland
  • Centrum Medyczne Pratia Gdynia /ID# 226431
    Gdynia, Pomeranian Voivodeship 81-338, Poland
  • Silmedic Sp. z o.o. /ID# 226457
    Katowice, Silesian Voivodeship 40-282, Poland
  • EuroMedis sp. z o.o. /ID# 226413
    Szczecin, West Pomeranian Voivodeship 70-111, Poland
  • MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak /ID# 226417
    Wroclaw, 52-210, Poland
  • Duplicate_Pusan National University Hospital /ID# 231416
    Busan, Busan Gwang Yeogsi 49241, South Korea

Showing the first 100 of 116 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Ashina S, Ashina M, Holle-Lee D, Tassorelli C, Cho SJ, He MY, De Abreu Ferreira R, Gandhi P, Smith JH, Pfleeger K, Trugman JM. Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine. Cephalalgia. 2025 Aug;45(8):3331024251365206. doi: 10.1177/03331024251365206. Epub 2025 Aug 19. PubMed 40831083 ↗

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Oct 2025, 56 months.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 56 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2020
First posted
Dec 28, 2020
StartActual
Feb 19, 2021
Primary completionActual
Oct 20, 2025
CompletionActual
Oct 20, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04686136
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 28, 2020
Start date
Feb 19, 2021
Primary completion
Oct 20, 2025
Completion
Oct 20, 2025
Last update
Dec 18, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atogepant

Start the discussion